Introduction
Pulmonary fungus infection is gradually becoming a problem in primary health care. Incidence of pulmonary fungus infections is increasing with the ageing of the population, the widespread use of immunosuppressants and broad spectrum antibiotics. Primary health-care institutions face particular challenges in treating pulmonary fungus infections due to resource and technical constraints, but the disease can still be dealt with effectively through scientifically sound methods to improve patient cure and quality of life.
II. Diagnosis points for pulmonary fungus infections
(i) Medical history collection
Detailed information is provided on the patient ‘ s medical history, including whether he has recently used broad spectrum antibiotics, sugar-coated hormones, immunosuppressants, chronic diseases (e.g. diabetes mellitus, chronic obstructive pulmonary diseases, etc.), organ transplant history, history of malignant neoplasms and history of leaching. These factors can increase the risk of cogil infection in the lungs. At the same time, the timing and severity of the patient ‘ s symptoms are known, such as cough, the nature of cough (with blood threads, freezing samples, etc.), heat (low or high heat, continuity or intermittentity), respiratory difficulties, etc.
(ii) Medical examination
Emphasis is placed on the examination of lung signs, including the frequency of breathing, rhythms, dry and wet voice, pleural friction, etc. At the same time, care is taken of the whole body condition of the patient, such as the absence of wasting and the swelling of the shallow lymphoma, which can be of some assistance in determining the severity of the disease and the possible sources of infection.
(iii) Complementary inspection
1. Visual inspection
An abnormal shading of the lungs, such as placards, ectoplasms, empty holes, etc., can be found in the X-rays, which are often found in primary health care facilities, but are less sensitive to early pathologies than CT. The conditions for CT tests can provide a clearer picture of lung pathologies, such as the possible transmutation of fungus infections, the new month, etc., and help to diagnose and identify the diagnosis.
Laboratory inspection
– Sluice testing: finding fungus and spores through sluice coating, although relatively low positive, is easy. Cultivation can determine the fungus species, but attention needs to be paid to the quality of specimen collection and the prevention of pollution.
– Blood tests: these include blood routines (observation of white cell count and classification, possibly normal or mild increase in white cells in the case of fungus infection), C reaction proteins (possible increase), blood biochemical examinations (knows the liver and kidney function of the patient, etc.) to inform follow-up treatment, since antimony drugs may have liver and kidney toxicity. In cases where the condition is more serious or difficult to diagnose, a serum half-milk glucose test (GM test), 1,3-beta-D-polymal sugar test (G test), etc., may be considered, but these examinations may require out-of-country testing at the grass-roots level.
III. Treatment strategy for pulmonary fungus infections
(i) General treatment
For patients with less serious and basic diseases, the treatment of basic diseases, such as the control of blood sugar and the improvement of lung function, is actively pursued. At the same time, the patient is provided with nutritional support and sufficient calorie and protein intake is guaranteed to increase the body ‘ s immunity. For patients with respiratory difficulties, treatment can be provided for symptoms such as oxygen.
(ii) Antimony treatment
1. Fluorinated condensers
For pyromoccal infections, especially white pyromoccus, fluorine is optional if the disease is relatively light. When using fluorine in primary health-care facilities, care is taken to adjust the dose and to make use of the drug rational according to the patient ‘ s kidney function. At the same time, patients are closely monitored for adverse reactions such as nausea, vomiting, rashes, etc.
2. Ictarconium
It is an option for some non-white mercuric or mild fungus infections. Ictarconium has both oral solution and capsule types, with high bioavailability of oral solution. In the course of use, attention is paid to the interaction of drugs with other drugs, such as certain anti-heart disorders, blood resins, etc., which may increase adverse reactions.
3. Penecin B
In primary health-care institutions, if the patient is seriously ill and is resistant to other drugs or pulmonary fungus infections with poor effect, the use of cocin B may be considered, but due to serious side effects such as renal toxicity, it needs to be used with caution. The electrolyte of the patient ‘ s kidney function, blood potassium, etc. can be closely monitored, starting with a small dose. Use may be accompanied by the use of a number of measures to mitigate adverse effects, such as the use of anti-groupamines to mitigate heat, cold warfare, etc.
(iii) Medical Aid in Chinese Medicine
At the grass-roots level, Chinese medicine can be used in accordance with the principles of medical evidence. For pulmonary fungus infections in the form of pulmonary proofs such as coughs, coughs, fevers, etc., accelerants can be used, such as accelerant accelerants such as acne, guacamole, semi-summer, chonams, platinum, almonds, acne, sauergens, and so on. The Chinese medicine reduces the patient ‘ s symptoms to some extent, regulates the body ‘ s immune function, and improves the treatment ‘ s efficacy in coordination with antimony drugs, while some of the Chinese medicine may have some antifluent activity.
IV. Surveillance and referral
(i) Disease surveillance
During the treatment, changes in the patient ‘ s symptoms, such as cough, cough, fever, respiratory difficulties, are closely observed. Laboratory indicators such as blood protocol, liver and kidney function, as well as chest image tests are regularly reviewed to assess the effects of treatment and the adverse effects of the drug. If the patient ‘ s symptoms are aggravated during treatment or new symptoms, such as chromosomiasis, severe chest pain, etc., are to be adjusted in a timely manner.
(ii) Referral
In the event of difficulties encountered in the course of diagnosis and treatment at the primary level, such as lack of a clear diagnosis, serious condition and lack of response to initial treatment, and serious complications (such as haemorrhaging, respiratory failure, etc.), the patient should be referred to a higher level in a timely manner to ensure more specialized treatment.
V. Preventive measures
At the grass-roots level, the management of drug use, including antibiotics and sugar-coated hormones, should be strengthened to avoid abuse. Preventive education is provided to patients with low immune functions, such as the elderly, diabetics, patients with leachate, etc., such as personal hygiene and indoor ventilation. At the same time, hospital infection control is being strengthened, medical equipment is being strictly sterilized to prevent cross-infection and to reduce the incidence of pulmonary fungus infection from the source.
In general, primary health-care facilities are better equipped to cope with the disease through accurate diagnosis, scientifically sound treatment, close case surveillance and effective preventive measures to ensure the health of patients.
